Naoki Terasaka

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. doi HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
    Alan R Tall
    Division of Molecular Medicine, Department of Medicine, Columbia University, New York, NY 10032, USA
    Cell Metab 7:365-75. 2008
  2. doi ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase
    Naoki Terasaka
    Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168 St, New York, NY 10032, USA
    Arterioscler Thromb Vasc Biol 30:2219-25. 2010
  3. pmc ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet
    Naoki Terasaka
    Division of Molecular Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
    J Clin Invest 118:3701-13. 2008
  4. pmc High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1
    Naoki Terasaka
    Division of Molecular Medicine, Department of Medicine, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 104:15093-8. 2007
  5. pmc Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice
    Laurent Yvan-Charvet
    Division of Molecular Medicine, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Invest 117:3900-8. 2007
  6. ncbi Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice
    Yoshihisa Okamoto
    Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
    Circulation 106:2767-70. 2002
  7. ncbi Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor
    Toshimori Inaba
    Department of Medicine and Pathophysiology, Graduate School of Frontier Bioscience, Osaka University, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    J Biol Chem 278:21344-51. 2003
  8. ncbi T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice
    Naoki Terasaka
    Pharmacology and Molecular Biology Research Laboratories, Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    FEBS Lett 536:6-11. 2003
  9. ncbi ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice
    Naoki Terasaka
    Pharmacology and Molecular Biology Research Laboratories, Sankyo Co Ltd, 1 2 58 Hiromachi, Tokyo, Japan
    Atherosclerosis 190:239-47. 2007
  10. ncbi Liver X receptor agonists inhibit tissue factor expression in macrophages
    Naoki Terasaka
    Pharmacology and Molecular Biology Research Laboratories, Sankyo Co Ltd, Tokyo, Japan
    FEBS J 272:1546-56. 2005

Collaborators

Detail Information

Publications11

  1. doi HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
    Alan R Tall
    Division of Molecular Medicine, Department of Medicine, Columbia University, New York, NY 10032, USA
    Cell Metab 7:365-75. 2008
    ..A variety of approaches to increasing HDL may eventually be successful in treating atherosclerosis...
  2. doi ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase
    Naoki Terasaka
    Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168 St, New York, NY 10032, USA
    Arterioscler Thromb Vasc Biol 30:2219-25. 2010
    ..To investigate whether cholesterol efflux to high-density lipoprotein (HDL) via ATP-binding cassette transporter G1 (ABCG1) modulates the interaction of caveolin (Cav) 1 and endothelial NO synthase (eNOS)...
  3. pmc ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet
    Naoki Terasaka
    Division of Molecular Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
    J Clin Invest 118:3701-13. 2008
    ..Our data suggest that ABCG1 and HDL maintain EC function in HCD-fed mice by promoting efflux of cholesterol and 7-oxysterols and preserving active eNOS dimer levels...
  4. pmc High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1
    Naoki Terasaka
    Division of Molecular Medicine, Department of Medicine, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 104:15093-8. 2007
    ..These findings indicate a specific role for ABCG1 in promoting efflux of 7-ketocholesterol and related oxysterols from macrophages onto HDL and in protecting these cells from oxysterol-induced cytotoxicity...
  5. pmc Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice
    Laurent Yvan-Charvet
    Division of Molecular Medicine, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Invest 117:3900-8. 2007
    ..These results suggest that the combined effects of ABCA1 and ABCG1 in mediating macrophage sterol efflux are central to the antiatherogenic properties of HDL...
  6. ncbi Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice
    Yoshihisa Okamoto
    Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
    Circulation 106:2767-70. 2002
    ..The current study investigated whether the increased plasma adiponectin could actually reduce atherosclerosis in vivo...
  7. ncbi Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor
    Toshimori Inaba
    Department of Medicine and Pathophysiology, Graduate School of Frontier Bioscience, Osaka University, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    J Biol Chem 278:21344-51. 2003
    ..Our results demonstrate that Angptl3 is a direct target of LXR and that induction of hepatic Angptl3 accounts for hypertriglyceridemia associated with the treatment of LXR ligand...
  8. ncbi T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice
    Naoki Terasaka
    Pharmacology and Molecular Biology Research Laboratories, Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    FEBS Lett 536:6-11. 2003
    ..T-0901317 also significantly induced cholesterol efflux activity in peritoneal macrophages. These results suggest that LXR ligands may be useful therapeutic agents for the treatment of atherosclerosis...
  9. ncbi ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice
    Naoki Terasaka
    Pharmacology and Molecular Biology Research Laboratories, Sankyo Co Ltd, 1 2 58 Hiromachi, Tokyo, Japan
    Atherosclerosis 190:239-47. 2007
    ..These data indicate that CS-505 can reduce and stabilize atherosclerotic lesions. This antiatherosclerotic activity is exerted via both cholesterol lowering and direct ACAT inhibition in plaque macrophages...
  10. ncbi Liver X receptor agonists inhibit tissue factor expression in macrophages
    Naoki Terasaka
    Pharmacology and Molecular Biology Research Laboratories, Sankyo Co Ltd, Tokyo, Japan
    FEBS J 272:1546-56. 2005
    ..These findings indicate that activation of LXR results in reduction of TF expression, which may influence atherothrombosis in patients with vascular disease...
  11. ncbi Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe
    Ken Kitayama
    Pharmacology and Molecular Biology Research Laboratories, Sankyo Co, Ltd, Tokyo, Japan
    Eur J Pharmacol 540:121-30. 2006
    ..Despite similar cholesterol lowering, fatty streak area reduction was greater by 10 mg/kg. These results suggest that ACAT1/2 dual inhibitor pactimibe has anti-atherosclerotic potential beyond its plasma cholesterol-lowering activity...